Edesa Biotech, Inc. logo

EDSA: Edesa Biotech, Inc.

Stock

About

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Website
www.edesabiotech.com
Year Founded
2007
Employees
16
Sector
Health Care
HQ Location
Markham, undefined

Current Value

$2.40

1 Year Return

-$0.96
-28.57%

Key Details

Market Cap

$7.70M

P/E Ratio

-1.38

1Y Stock Return

-29.88%

1Y Revenue Growth

0.00%

Dividend Yield

0.00%

Price to Book

2.7

Strategies that include
EDSA

High risk

$1,000

1.54%

Contrarian Picks

speculation
maximum growth

You better have a strong stomach if this portfolio interests you; it certainly isn't for the faint of heart. These are smaller companies that aren't being traded very heavily and while they may be cheap (PE <15), they have a lackluster TTM performance to show for it (<0%). Are they stocks to avoid or a list of potential hidden gems?

Top Sector

Health Care

Top Holdings

Rocky Brands, Inc logo
Smart Powerr Corp logo
Consolidated Water Co. Ltd. logo
Vasta Platform Ltd - Ordinary Shares Class A logo
SoundThinking Inc logo

Return

-5.79%

Expense Ratio

0.00%

Holdings

65

Create your own
strategy with

EDSA
Three dimensional double logo

Stock's related to
EDSA

Correlated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
GRAL38.02%$629.34M+10.18%0.00%
HRMY35.18%$2.00B+12.42%0.00%
AKRO27.34%$2.23B+78.73%0.00%
KFRC26.11%$1.17B-2.92%0.62%
KOD24.65%$390.99M+157.09%0.00%
ANGO23.69%$290.13M+5.47%0.00%
SRRK23.22%$3.55B+161.79%0.00%
GYRE22.92%$1.11B-26.34%0.00%
CMPS22.69%$307.21M-26.39%0.00%
FUN22.32%$4.85B-11.91%0.00%
PRPL22.22%$105.23M+16.73%0.00%
FDMT21.82%$350.87M-42.93%0.00%
GBIO21.79%$94.85M-5.96%0.00%
PBYI21.65%$157.08M-15.79%0.00%
MRNS21.47%$18.16M-95.61%0.00%
KURA21.29%$870.95M+9.70%0.00%
NERV21.25%$15.81M-65.28%0.00%
OPRT21.23%$135.25M+39.26%0.00%
BW21.19%$185.80M+13.87%0.00%
GNW21.19%$3.31B+25.16%0.00%

Uncorrelated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
BGC<0.01%$4.62B+47.02%0.73%
CLW-0.01%$449.98M-25.97%0.00%
QURE0.01%$347.54M+0.42%0.00%
TPG-0.01%$6.72B+94.28%2.41%
BALY0.02%$729.56M+45.03%0.00%
ARM0.02%$147.50B+126.61%0.00%
KOP0.02%$795.15M-14.25%0.71%
ONON-0.03%$18.74B+96.21%0.00%
EXAS-0.03%$11.42B-6.05%0.00%
LAUR0.03%$2.84B+44.18%0.00%
GGG-0.03%$15.32B+10.10%1.13%
MCO0.03%$90.13B+33.02%0.68%
BECN-0.04%$6.95B+33.69%0.00%
FIZZ0.04%$4.67B+10.15%0.00%
HPK-0.04%$1.91B+0.80%1.06%
WDFC0.04%$3.75B+13.85%1.27%
SNN-0.05%$11.22B-1.11%2.91%
CVGI-0.05%$83.49M-64.39%0.00%
BXP0.05%$12.79B+26.93%4.84%
TU0.05%$23.39B-16.36%7.17%

ETF's related to
EDSA

News

Yahoo

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa’s Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million. The entity will purch

Yahoo

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024Dermatology Drug Development Summit, Boston, Mass., November 12-14, 2024LSX Investival Showcase, London, UK, November 1

Yahoo

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update EB05 Selected for U.S. Government Funded Study in ARDS In June 2024, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that EB05 (paridiprubart) was selected by the Biomedical Advanced Research and Development Authority (BARDA) for testing in a U.S. government-funded clinical trial to test three novel threat-agnostic

Yahoo

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development ...

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Design your own stock index

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.